Nature Medicine

Article	Citations
The proximal origin of SARS-CoV-2	3337
Temporal dynamics in viral shedding and transmissibility of COVID-19	2959
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	2700
Post-acute COVID-19 syndrome	2436
Antibody responses to SARS-CoV-2 in patients with COVID-19	2211
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections	2095
Extrapulmonary manifestations of COVID-19	1954
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes	1936
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19	1815
Chronic inflammation in the etiology of disease across the life span	1724
A global survey of potential acceptance of a COVID-19 vaccine	1629
An inflammatory cytokine signature predicts COVID-19 severity and survival	1573
Respiratory virus shedding in exhaled breath and efficacy of face masks	1492
A serological assay to detect SARS-CoV-2 seroconversion in humans	1436
Attributes and predictors of long COVID	1291
Age-dependent effects in the transmission and control of COVID-19 epidemics	1188
Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy	1115
A single-cell atlas of the peripheral immune response in patients with severe COVID-19	1098
Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding	1096
Real-time tracking of self-reported symptoms to predict potential COVID-19	1045
Digital technology and COVID-19	866
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China	858
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19	805
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	784
Long-term cardiovascular outcomes of COVID-19	761

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	730
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	690
A dynamic COVID-19 immune signature includes associations with poor prognosis	661
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19	608
Digital technologies in the public-health response to COVID-19	600
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers	574
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	563
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	546
Seasonal coronavirus protective immunity is short-lasting	544
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease	538
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia	538
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	473
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	459
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	454
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation	444
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma	441
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong	437
SARS-CoV-2 infection of the oral cavity and saliva	432
Determinants of COVID-19 disease severity in patients with cancer	431
Single-cell immune landscape of human atherosclerotic plaques	430
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants	422
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration	416
Immune determinants of COVID-19 disease presentation and severity	414
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	405
Looking beyond COVID-19 vaccine phase 3 trials	402
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma	388
Infection of bat and human intestinal organoids by SARS-CoV-2	387
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein	383
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	373
Joint international consensus statement for ending stigma of obesity	373
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	369
Undulating changes in human plasma proteome profiles across the lifespan	367
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda	362
Understanding COVID-19 vaccine hesitancy	361
Long COVID in a prospective cohort of home-isolated patients	360
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	356
If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future	351
Single-cell multi-omics analysis of the immune response in COVID-19	349
Human postprandial responses to food and potential for precision nutrition	342
AI in health and medicine	342
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial	338
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR	338
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	336
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	332
Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks	332
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	331
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19	326
On the responsible use of digital data to tackle the COVID-19 pandemic	323
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	318
Clinical lessons learned from the first leg of the CAR T cell journey	313

Long COVID after breakthrough SARS-CoV-2 infection	313
Targeting metastatic cancer	312
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	311
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	309
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	308
Disease and healthcare burden of COVID-19 in the United States	308
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China	304
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	303
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity	302
Sixteen novel lineages of SARS-CoV-2 in South Africa	301
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors	297
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	296
Using human genetics to understand the disease impacts of testosterone in men and women	296
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	293
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes	291
Human–computer collaboration for skin cancer recognition	291
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease	291
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	290
Modeling COVID-19 scenarios for the United States	290
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	289
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	289
Biomarkers for neurodegenerative diseases	287
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension	286
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	285
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers	283
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection	280
Intratumoral heterogeneity in cancer progression and response to immunotherapy	279
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer	275
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	274
SARS-CoV-2 variants of concern are emerging in India	271
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	271
A deep learning system for differential diagnosis of skin diseases	270
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report	269
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	267
A rectal cancer organoid platform to study individual responses to chemoradiation	265
Brown adipose tissue is associated with cardiometabolic health	264
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	264
Wearable sensor data and self-reported symptoms for COVID-19 detection	263
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	262
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	262
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	261
Deep learning-based classification of mesothelioma improves prediction of patient outcome	259
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	258
Partial recovery of visual function in a blind patient after optogenetic therapy	257
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters	256
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries	256
Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States	256
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	254
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling	249
Deep learning in histopathology: the path to the clinic	248
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	247
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors	245
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	243
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	242
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis	239
Combating COVID-19: health equity matters	238
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle	235
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	234
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	234
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	233
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial	233
Regenerative lineages and immune-mediated pruning in lung cancer metastasis	233
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands	232
Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units	229
Symptoms and risk factors for long COVID in non-hospitalized adults	229
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	228
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers	228
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	227
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin	226
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial	225
Caring for patients with cancer in the COVID-19 era	220
A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research	219
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	218
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial	216
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection	216
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	216
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	215
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease	215
Plasma protein patterns as comprehensive indicators of health	214
A single-cell landscape of high-grade serous ovarian cancer	211

A stochastic agent-based model of the SARS-CoV-2 epidemic in France	211
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration	209
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension	209
An immune-cell signature of bacterial sepsis	206
Toward personalized treatment approaches for non-small-cell lung cancer	202
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	202
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma	201
Targeting the HIF2–VEGF axis in renal cell carcinoma	200
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	196
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade	196
Sex differences in cardiometabolic disorders	194
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	194
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	193
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist	192
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial	190
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	188
Federated learning for predicting clinical outcomes in patients with COVID-19	186
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma	183
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	180
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	180
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	177
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	176
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures	175
Axes of a revolution: challenges and promises of big data in healthcare	174
Modeling shield immunity to reduce COVID-19 epidemic spread	173
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	173
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	171
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	170
Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR	168
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	168
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy	168
Personal aging markers and ageotypes revealed by deep longitudinal profiling	167
Crowding and the shape of COVID-19 epidemics	167
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	166
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial	165
Using a real-world network to model localized COVID-19 control strategies	164
A guide to immunotherapy for COVID-19	163
Microglial activation and tau propagate jointly across Braak stages	163
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma	163
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	163
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring	162
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	161
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies	159
COVID-19 dynamics after a national immunization program in Israel	159
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study	159
Vaginal microbiome transplantation in women with intractable bacterial vaginosis	159
High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis	158
Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome	157
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	157
Therapeutic base editing of human hematopoietic stem cells	157
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2	157
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study	155
Viable bacterial colonization is highly limited in the human intestine in utero	155
Early prediction of circulatory failure in the intensive care unit using machine learning	154
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer	154
Delayed production of neutralizing antibodies correlates with fatal COVID-19	154
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models	154
Understanding the rise of cardiometabolic diseases in low- and middle-income countries	153
Sensory feedback restoration in leg amputees improves walking speed, metabolic cost and phantom pain	153
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma	153
A correlate of protection for SARS-CoV-2 vaccines is urgently needed	152
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma	152
Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients	151
Articular cartilage regeneration by activated skeletal stem cells	150
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk	149
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors	149
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology	149
Prediction of gestational diabetes based on nationwide electronic health records	149
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	148
The distribution of cellular turnover in the human body	148
Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy	148
Closed-loop neuromodulation in an individual with treatment-resistant depression	147
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma	147
Avoidable flaws in observational analyses: an application to statins and cancer	147
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	147
Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity	147
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors	146
Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes	145
COVID-19 in Africa: the spread and response	144
Vaccine development for emerging infectious diseases	144
Predicting conversion to wet age-related macular degeneration using deep learning	143
Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease	143
Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes	142
A luminal unfolding microneedle injector for oral delivery of macromolecules	141
Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel	140
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	140
Developing neoantigen-targeted T cell–based treatments for solid tumors	139
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease	139
Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease	139
Unexplained post-acute infection syndromes	138
Lentiviral gene therapy for X-linked chronic granulomatous disease	137
Exercise reduces inflammatory cell production and cardiovascular inflammation via instruction of hematopoietic progenitor cells	137
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland	137
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	137
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy	136
Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: The STARD-AI Steering Group	134
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes	133
Prospective virome analyses in young children at increased genetic risk for type 1 diabetes	133
Engineered immunogen binding to alum adjuvant enhances humoral immunity	132
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	131
Modeling transmission of SARS-CoV-2 Omicron in China	131
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers	130
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	130
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis	130
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research	130
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial	130
A roadmap to increase diversity in genomic studies	129
Colibactin DNA-damage signature indicates mutational impact in colorectal cancer	129
Global maps of travel time to healthcare facilities	129
Prediction of mortality from 12-lead electrocardiogram voltage data using a deep neural network	128
A neuroimaging biomarker for striatal dysfunction in schizophrenia	126
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster	125
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma	124
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer	124
Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19	124
Acute and postacute sequelae associated with SARS-CoV-2 reinfection	123
Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus	123
COVID-19 in humanitarian settings and lessons learned from past epidemics	123
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis	122
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse	122
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis	121
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium	121
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer	120
Wearable-device-measured physical activity and future health risk	120
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial	119
Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice	119
Long-term neurologic outcomes of COVID-19	119
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	117
Cellular senescence and senolytics: the path to the clinic	116
Reporting guidelines for human microbiome research: the STORMS checklist	116
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial	116
Humoral signatures of protective and pathological SARS-CoV-2 infection in children	116
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	115
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease	115
A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia	113
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial	113
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1	112
Emergence of a novel human coronavirus threatening human health	111
Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil	111
Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy	111
Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial	109
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	108
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	108
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines	108
Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota	107

Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae	106
Increased global integration in the brain after psilocybin therapy for depression	106
Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environment	106
An algorithmic approach to reducing unexplained pain disparities in underserved populations	106
The potential public health consequences of COVID-19 on malaria in Africa	105
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy	105
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	105
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021	105
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases	104
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer	104
Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19	103
Myocardial infarction accelerates breast cancer via innate immune reprogramming	103
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma	102
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer	102
Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma	102
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis	101
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study	101
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers	101
Safety profile of autologous macrophage therapy for liver cirrhosis	101
Population genetic screening efficiently identifies carriers of autosomal dominant diseases	101
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial	101
Modeling human adaptive immune responses with tonsil organoids	101
State-dependent responses to intracranial brain stimulation in a patient with depression	101
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma	101
Single-cell atlas of colonic CD8+ T cells in ulcerative colitis	100
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	100
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms	99
A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys	99
AI in medicine must be explainable	99
Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia	99
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma	98
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis	97
A neuroimaging biomarker for sustained experimental and clinical pain	96
Misinformation: susceptibility, spread, and interventions to immunize the public	96
Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial	96
An overdose surge will compound the COVID-19 pandemic if urgent action is not taken	95
Neuronal defects in a human cellular model of 22q11.2 deletion syndrome	95
Wearable sensors enable personalized predictions of clinical laboratory measurements	93
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)	93
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents	92
Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19	92
Targeting the gut and tumor microbiota in cancer	91
Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake	91
Maternal cannabis use in pregnancy and child neurodevelopmental outcomes	91
Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report	91
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial	91
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model	90
Effect of salt substitution on community-wide blood pressure and hypertension incidence	90
Use of apps in the COVID-19 response and the loss of privacy protection	90
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes	90
Learning from clinical trials of neoadjuvant checkpoint blockade	90
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity	89
iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates	89
COVID-19 and resilience of healthcare systems in ten countries	88
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19	88
The role of exome sequencing in newborn screening for inborn errors of metabolism	88
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge	88
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing	86
Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease	86
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial	86
A framework for the investigation of rare genetic disorders in neuropsychiatry	86
Fast and frugal innovations in response to the COVID-19 pandemic	85
Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants	84
‘Test, re-test, re-test’: using inaccurate tests to greatly increase the accuracy of COVID-19 testing	84
Reporting guidelines for clinical trials evaluating artificial intelligence interventions are needed	84
AlphaFold heralds a data-driven revolution in biology and medicine	84
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	83
Multimodal biomedical AI	83
Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans	83
Distinction of lymphoid and myeloid clonal hematopoiesis	83
The effects of tobacco control policies on global smoking prevalence	82
Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition	81
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial	80
Recommendations for measuring HIV reservoir size in cure-directed clinical trials	80
Pan-viral serology implicates enteroviruses in acute flaccid myelitis	80
An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease	80
DECIDE-AI: new reporting guidelines to bridge the development-to-implementation gap in clinical artificial intelligence	80
A population-based phenome-wide association study of cardiac and aortic structure and function	79
A human three-dimensional neural-perivascular ‘assembloid’ promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology	79
Preventing dysbiosis of the neonatal mouse intestinal microbiome protects against late-onset sepsis	79
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV	79
IL-1-driven stromal–neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies	78
Regulatory, safety, and privacy concerns of home monitoring technologies during COVID-19	78
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy	77
Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome	77
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial	77
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials	77
Redefining critical illness	76
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years	76
Development and validation of serological markers for detecting recent Plasmodium vivax infection	76
Integrated single-cell analysis of multicellular immune dynamics during hyperacute HIV-1 infection	76
Calming the cytokine storm in COVID-19	76
Association of lead-exposure risk and family income with childhood brain outcomes	76
A validated predictive algorithm of post-traumatic stress course following emergency department admission after a traumatic stressor	76
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial	76
Adipose lipid turnover and long-term changes in body weight	75
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial	75
Preparing for a responsible lockdown exit strategy	75
Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection	74
Performance of plasma phosphorylated tau 181 and 217 in the community	74
The effect of LRRK2 loss-of-function variants in humans	74
Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions	74
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil	74
A maternal serum metabolite ratio predicts fetal growth restriction at term	73
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial	73
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial	73
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial	73
Transcriptional mediators of treatment resistance in lethal prostate cancer	72
Increased circulation time of Plasmodium falciparum underlies persistent asymptomatic infection in the dry season	72
China’s response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response	72
Delivering precision oncology to patients with cancer	72
Integrative microbiomics in bronchiectasis exacerbations	72
XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis	71
Acute liver failure is regulated by MYC- and microbiome-dependent programs	70
Simultaneous detection of genotype and phenotype enables rapid and accurate antibiotic susceptibility determination	70
A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics	70
Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year	70
Engineering transplantable jejunal mucosal grafts using patient-derived organoids from children with intestinal failure	70
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial	69
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial	69
Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis	69
Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa	69
Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection	69
Genomic copy number predicts esophageal cancer years before transformation	68
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma	68
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER	68
Anomalously warm temperatures are associated with increased injury deaths	68
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial	67
Trans-biobank analysis with 676,000 individuals elucidates the association of polygenic risk scores of complex traits with human lifespan	67
Comprehensive large-scale nucleic acid–testing strategies support China’s sustained containment of COVID-19	67
Causation or confounding: why controls are critical for characterizing long COVID	67
Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI	66
Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalus	66
Engineered cellular immunotherapies in cancer and beyond	66
IL-8 and cancer prognosis on immunotherapy	66
A combined risk score enhances prediction of type 1 diabetes among susceptible children	66
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis	65
Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans	65
Human SNORA31 variations impair cortical neuron-intrinsic immunity to HSV-1 and underlie herpes simplex encephalitis	65
Plasma metabolites to profile pathways in noncommunicable disease multimorbidity	65
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells	65
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication	64
The landscape of mRNA nanomedicine	64
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma	64
Single-cell genomic approaches for developing the next generation of immunotherapies	64
A clonal expression biomarker associates with lung cancer mortality	64
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis	64
How COVID-19 shaped mental health: from infection to pandemic effects	63
Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency	63
Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS	63
High-frequency neuromodulation improves obsessive–compulsive behavior	63
Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals	63
Individual and community-level risk for COVID-19 mortality in the United States	62
100 years of insulin: celebrating the past, present and future of diabetes therapy	62
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy	62
Deep learning models for electrocardiograms are susceptible to adversarial attack	62
Autism risk in offspring can be assessed through quantification of male sperm mosaicism	62
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i	62
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor	62
SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies	61
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial	61
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy	61
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial	61
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial	60
Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals	60
Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer	60
Generation of functional lungs via conditional blastocyst complementation using pluripotent stem cells	59
Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce	59
Equitable allocation of COVID-19 vaccines in the United States	59
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2	59
Responding to the hidden pandemic for healthcare workers: stress	59
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia	58
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial	58
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes	58
Time to evaluate COVID-19 contact-tracing apps	58
Microbiome and metabolome features of the cardiometabolic disease spectrum	57
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial	57
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial	57
Meeting the challenge of long COVID	57
Altered perivascular fibroblast activity precedes ALS disease onset	57
Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure	56
Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys	56
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial	56
Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin	55
Reduction in life expectancy in Brazil after COVID-19	55
A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques	55
Studying severe long COVID to understand post-infectious disorders beyond COVID-19	55
Automated opportunistic osteoporotic fracture risk assessment using computed tomography scans to aid in FRAX underutilization	55
The French health pass holds lessons for mandatory COVID-19 vaccination	55
CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption	54
PrEP rollout in Africa: status and opportunity	54
Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis	54
A dangerous measles future looms beyond the COVID-19 pandemic	54
Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs	54
Ten recommendations for supporting open pathogen genomic analysis in public health	54
Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models	54
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave	53
The future of early cancer detection	53
Life expectancy and mortality in 363 cities of Latin America	53
Nigeria responds to COVID-19; first case detected in sub-Saharan Africa	53